CareLit Fachartikel

Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?

Berntorp, E. · Zeitschrift für Orthopädie und Unfallchirurgie · 2017 · Heft 01 · S. 53 bis 57

Dokument
612057
CareLit-ID
Jahr
2017
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Orthopädie und Unfallchirurgie
Autor:innen
Berntorp, E.
Ausgabe
Heft 01 / 2017
Jahrgang 37
Seiten
53 bis 57
Erschienen: 2017-01-01 00:00:00
ISSN
0720-9355;2567-5761
DOI
10.5482/hamo-16-10-0040

Zusammenfassung

SummaryInhibitor development in haemophilia is a serious complication to treatment with factor concentrates. Since the advent of more pure products, especially developed using recombinant DNA technology, some studies have shown an increased incidence of inhibitors in previously untreated patients (PUPs) receiving recombinant products whereas plasma-derived concentrates sometimes have been claimed to have a protective role, probably due to the content of von Willebrand factor (VWF). In fact, experiments indicate that the VWF may block uptake of factor VIII into macrophages for further processing to the immune sys…

Schlagworte

Factor Concentrates Recombinant Debate Development Haemophilia Products Studies Inhibitors Previously Patients Inhibitor Zeitschrift für Orthopädie und Unfallchirurgie